和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

已收盘 11-11 16:08:05

11.250

+0.190

+1.72%

最高11.260	最低10.880	成交量645.03万
今开11.000	昨收11.060	日振幅3.44%
总市值97.76亿	流通市值97.76亿	总股本8.69亿
成交额7,151万	换手率0.74%	流通股本8.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":11.25,"timestamp":1794384485003,"preClose":11.06,"halted":0,"volume":6450309,"delay":0,"changeRate":0.017179023508137388,"floatShares":869000000,"shares":869000000,"eps":0.11,"marketStatus":"已收盘","change":0.19,"latestTime":"11-11 16:08:05","open":11,"high":11.26,"low":10.88,"amount":71506404,"amplitude":0.034358,"askPrice":11.25,"askSize":71000,"bidPrice":11.24,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794447000000},"marketStatusCode":5,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":11.06,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.704059,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0516422952.EUR","LU0348766576.USD","LU0456827905.SGD","LU0540923850.HKD","LU1242518857.USD","LU0128522744.USD","01177","01801","LU1242518931.SGD","IE00BPRC5H50.USD","LU0039217434.USD","02142","LU0348783233.USD","LU1152091754.HKD","LU0228659784.USD","02616","01093","LU1226287529.USD","LU2097828474.EUR","LU1251922891.USD","LU0708995153.HKD","BK1583","09926","LU0594300179.USD","01877","06185","BK1515","06160","LU0823426308.USD","09995","LU1960683339.HKD","02269","09688","LU0320764243.SGD","LU1152091168.USD","LU0417516571.SGD","LU2488822045.USD","LU0315179316.USD","LU1188198961.HKD","BK1191","LU0634319403.HKD","601066","LU2097828714.EUR","KURE","LU1813983027.USD","KCE","LU0455707207.USD","LU2242644610.SGD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193311430","title":"和铂医药-B更新10月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1193311430","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193311430?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:06","pubTimestamp":1793887608,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年11月5日发布2026年10月的股份变动月报表。报告期内，公司法定注册股本保持不变，仍为20,000,000,000股，面值每股USD 0.000025，注册股本总额USD 500,000。报告显示，截至2026年10月31日，公司已发行股份由上月底的872,101,522股减少至869,890,522股；同期库藏股由31,834,000股增加至34,934,000股。公司确认其截至本月底继续符合香港联交所的公众持股量要求。此外，公司于当月多次进行股份回购，合计回购3,100,000股并将其列为库藏股，另有406,000股已回购但尚未正式注销。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123843646","title":"异动解读｜和铂医药-B盘中上涨5.03%，回购叠加创新药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1123843646","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123843646?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:41","pubTimestamp":1793846460,"startTime":"0","endTime":"0","summary":"11月5日，和铂医药-B盘中上涨5.03%，报10.65港元，成交额3035.0万港元。消息面上，公司11月4日于联交所场内回购20万股，耗资约195.68万港元，回购价介乎9.385港元至10.2港元；此前11月3日亦回购50万股，近期连续回购持续释放积极信号。同时，生物科技板块整体走强，百济神州、信达生物、康方生物、科伦博泰生物、三生制药均涨超5%。叠加公司首款产品巴托利单抗皮下注射液此前获批上市，市场对其基本面兑现预期有所强化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药盘中上涨，回购叠加创新药走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155895959","title":"和铂医药-B：11月4日回购20万股股份，耗资约195.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155895959","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155895959?lang=zh_cn&edition=full","pubTime":"2026-11-04 18:46","pubTimestamp":1793789213,"startTime":"0","endTime":"0","summary":"2026年11月4日，和铂医药-B发布翌日披露报表，显示公司于当日于香港联交所场内回购普通股200,000股，占回购前已发行股本的0.023%。本次回购每股价格介乎9.385港元至10.2港元，平均约9.783975港元，合计耗资约195.68万港元。公司确认，所有回购及股份发行事项均已获得董事会授权，并遵守香港联交所相关上市规则及适用法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B：11月4日回购20万股股份，耗资约195.68万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132124337","title":"异动解读｜和铂医药-B盘中上涨5.16%，回购叠加创新药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1132124337","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132124337?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:32","pubTimestamp":1793770334,"startTime":"0","endTime":"0","summary":"11月4日，和铂医药-B盘中上涨5.16%，报9.915港元，成交额4138.18万港元。消息面上，公司11月3日于联交所场内回购50万股，耗资约471.75万港元，回购价为9.31港元至9.69港元；截至目前累计回购380万股，占回购授权通过当日已发行股本约0.44%。同时，生物科技板块走强，CXO及创新药方向活跃，和铂医药-B当日亦被纳入上涨个股之列。此前公司核心产品巴托利单抗皮下注射液已获批上市，用于治疗全身型重症肌无力，持续强化基本面预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药回购利好，盘中放量上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680519700","title":"CXO板块逆市走强 百济神州（06160）涨5.14%、凯莱英（06821）涨4.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680519700","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680519700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:34","pubTimestamp":1793759693,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块逆市走强，百济神州 涨5.14%，凯莱英涨4.19%，药明康德涨3.92%，药明生物涨3.58%，科伦博泰生物涨2.89%，药明合联涨2.44%，和铂医药-B涨1.76%，康龙化成涨1.46%，和黄医药涨1.17%。湘财证券表示，CXO龙头药明康德三季报超预期、指引上修，印证CXO由周期修复转向CRDMO结构性重估。维持药品行业“买入”评级，建议关注创新化学制剂及创新药产业链上游CXO公司。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995187","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","LU0051755006.USD","LU1720050803.USD","688235","002821","02142","LU0348766576.USD","BK1574","LU0823426480.USD","06821","00013","LU0502904849.HKD","LU0463099449.HKD","LU0326950275.SGD","LU0828237510.HKD","LU0516422440.USD","03759","LU0128522744.USD","LU0455707207.USD","LU0043850808.USD","LU2045819591.USD","LU0456827905.SGD","LU0588546209.SGD","KURE","02359","LU0229945570.USD","LU0327786744.USD","02269","06990","LU0128526141.USD","02268","BK1141","LU3063872942.SGD","SG9999002463.SGD","LU0072913022.USD","WX","LU0359202008.SGD","LU0501845795.SGD","LU2476274308.USD","LU0320764243.SGD","ONC","LU2476274720.SGD","LU1719994722.HKD","LU0516423091.SGD","LU1242518857.USD","BK0132","06160","CXO","SG9999002562.SGD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154085272","title":"和铂医药-B回购50.00万股股份，涉资约471.75万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154085272","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154085272?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:46","pubTimestamp":1793713580,"startTime":"0","endTime":"0","summary":"和铂医药-B于2026年11月3日发布翌日披露报表，披露当日通过香港联交所场内回购普通股50.00万股，约占已发行股本的0.0575%，最高回购价每股9.69港元，最低回购价每股9.31港元，合计支付约471.75万港元。公司同时根据股份奖励计划发行41,000股新股，占已发行股本约0.0047%。该公司回购授权于2026年6月25日获股东批准，授权回购股份总数为8,682.37万股，截至目前已回购3,800,000股，占授权通过当日已发行股本约0.44%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B回购50.00万股股份，涉资约471.75万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680724794","title":"和铂医药-B(02142)11月3日斥资约471.75万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680724794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680724794?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:44","pubTimestamp":1793713479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年11月3日该公司斥资约471.75万港元回购50万股，回购价格为每股9.31至9.69港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680247977","title":"和铂医药-B(02142.HK)11月3日斥资约471.75万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680247977","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680247977?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:44","pubTimestamp":1793713479,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02142","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680775224","title":"和铂医药-B(02142)11月2日斥资195.14万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680775224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680775224?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:42","pubTimestamp":1793623363,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年11月2日斥资195.14万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176413009","title":"和铂医药-B11月2日回购200,000股并发行21,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1176413009","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176413009?lang=zh_cn&edition=full","pubTime":"2026-11-02 20:41","pubTimestamp":1793623292,"startTime":"0","endTime":"0","summary":"和铂医药-B于2026年11月2日发布公告，披露当日回购股份及已发行股本变动等情况。根据公告，公司当日于香港联交所场内回购200,000股普通股，占此前已发行股本约0.023%，每股回购价介乎9.43港元至9.97港元，合计支付约195.14万港元。此外，公司同日依据经股东批准的首次公开发行后股份奖励计划，向相关参与人发行了21,000股普通股，约占已发行股本的0.0024%。截至公告日，公司已累计回购3,300,000股，占该回购授权通过当日已发行股本的0.38%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B11月2日回购200,000股并发行21,000股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122766446","title":"和铂医药-B回购20万股股份，耗资约195.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122766446","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122766446?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:47","pubTimestamp":1793357250,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年10月30日发布翌日披露报表，公告日前后进行股份购回与已发行股本变动。公司于2026年10月30日在香港联交所场内回购普通股共计200,000股，占当日公司现有已发行股份的约0.023%。每股回购价格介乎9.48港元至10.06港元，合计涉资约195.24万港元。上述发行及回购完成后，公司于2026年10月30日的已发行股份总数变更为869,890,522股，库藏股总数为34,934,000股，合计904,824,522股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B回购20万股股份，耗资约195.24万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679975012","title":"和铂医药-B(02142)10月30日斥资约195.24万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679975012","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679975012?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:37","pubTimestamp":1793356649,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年10月30日该公司斥资约195.24万港元回购20万股，回购价格为每股9.48至10.06港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101726859","title":"和铂医药-B回购20万股，耗资约196.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101726859","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101726859?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:56","pubTimestamp":1793102203,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年10月27日发布翌日披露报表，披露股份回购及已发行股本变动等事项。2026年10月27日，公司在香港联交所场内回购股份20万股，占当日回购前已发行股本约0.023%，每股回购价介乎每股9.67港元至9.93港元，总付出对价约196.30万港元。回购完成后，公司库藏股数增至34,734,000股。期末公司已发行股本由869,843,522股增至869,894,522股，加上库藏股后合计904,628,522股。公司并确认上述股份回购及发行已遵守相关上市规则及适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B回购20万股，耗资约196.30万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678174125","title":"和铂医药-B(02142.HK)10月27日斥资196.3万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678174125","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678174125?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:50","pubTimestamp":1793101849,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155882124","title":"异动解读｜和铂医药-B盘中下跌5.11%，首款产品获批后股价继续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1155882124","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155882124?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:17","pubTimestamp":1793081851,"startTime":"0","endTime":"0","summary":"10月27日，和铂医药-B盘中下跌5.11%，报9.66港元，成交额4536.8万港元。此前披露的临床结果显示，巴托利单抗治疗组58.2%患者达成主要终点，安慰剂组为31.3%；公司并称其有权根据该产品在大中华区年度净销售额获得分级特许权使用费。尽管基本面催化明确，但当日生物科技板块整体偏弱，和铂医药-B股价仍出现回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B股价回调，首款产品获批后承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678157751","title":"Windward Bio纳斯达克IPO交表，核心产品来自和铂医药授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2678157751","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678157751?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:42","pubTimestamp":1793000573,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","07522","07568","BK1610","03086","03034","03455","02834","BK1161","09086","07261","09834","BK1147","02142","07266","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677991178","title":"招商证券国际：首予和铂医药(02142.HK)“增持”评级 目标价28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677991178","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677991178?lang=zh_cn&edition=full","pubTime":"2026-10-23 11:24","pubTimestamp":1792725840,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","BK1161","06099","02142","BK1564","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916728","title":"首款产品获批，和铂医药迈入“产品兑现期”","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916728","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916728?lang=zh_cn&edition=full","pubTime":"2026-10-23 10:04","pubTimestamp":1792721066,"startTime":"0","endTime":"0","summary":"从授权驱动到产品驱动，和铂医药的“产品兑现期”正式拉开大幕。","market":"fut","thumbnail":"https://img2.gelonghui.com/d273d-7642d569-af65-4cd9-8ae8-daf9771bd880.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-7642d569-af65-4cd9-8ae8-daf9771bd880.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/7117005","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02142","02170","BK1222","BK1583","BK1597","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918592","title":"和铂医药-B(02142)：巴托利单抗注射液(皮下注射)获NMPA批准上市用于治疗全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918592?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:13","pubTimestamp":1792714421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，中国国家药品监督管理局已批准巴托利单抗注射液上市，与常规治疗药物联用于治疗抗乙酰胆硷受体抗体阳性的成人全身型重症肌无力患者。巴托利单抗为公司根据上市规则第18A章的核心产品。巴托利单抗皮下注射为集团首款获批准产品，亦为首款在中国完成针对gMG患者全程临床开发的抗新生儿Fc受体疗法。集团有权根据巴托利单抗在大中华区的年度净销售额获得分级特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1766},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.2641},{"period":"6month","weight":-0.1312},{"period":"1year","weight":-0.1531},{"period":"ytd","weight":-0.0905}],"compareEarnings":[{"period":"1week","weight":0.0438},{"period":"1month","weight":0.0143},{"period":"3month","weight":-0.0347},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0785},{"period":"ytd","weight":-0.0419}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.031233},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057848},{"month":10,"riseRate":0,"avgChangeRate":-0.199935},{"month":11,"riseRate":0.833333,"avgChangeRate":0.237204},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}